Guideline Health Canada [Regulatives / Guidelines]

posted by khaoula – Algeria, 2014-11-23 18:35 (4235 d 07:53 ago) – Posting: # 13918
Views: 4,767

good evening everybody,
I have à question, I read an interessant topic in this guideline of Health Canada " Guidance for Industry: Conduct and Analysis of Bioavailability and Bioequivalence Studies - Part A: Oral Dosage Formulations Used for Systemic Effects (1992)", and I found the method of calculating the AUC ratio and Cmax ratio estimates and their confidence limits, based on data corrected for measured content, so the natural logarithm of (Measured content of R/ Measured content of T)of the analytical dosage before the study is used as a corrective factor to calculate AUC ratio and Cmax ratio.
my question is: the part of this guideline that addresses this topic disappeared in the new guideline "Conduct and Analysis of Comparative Bioavailability Studies and Comparative Bioavailability standards: Formulations used for Systemic Effects" 2012, and I did'nt find this information anywhere

Why? is anyone have an answer ? is this method acceptable by others authorities like FDA and EMA?
thank you

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
345 visitors (0 registered, 345 guests [including 19 identified bots]).
Forum time: 03:29 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5